5-MeO-MiPT
 | |
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
show
IUPAC name | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.223.426  |
| Chemical and physical data | |
| Formula | C15H22N2O |
| Molar mass | 246.354 g·mol−1 |
| 3D model (JSmol) | |
show
SMILES | |
show
InChI | |
  (what is this?) | |
5-MeO-MiPT is a psychedelic and hallucinogenic drug, used by some as an entheogen. It has structural and pharmacodynamic properties similar to the drugs 5-MeO-DiPT, DiPT, and MiPT. It is commonly used as a "substitute" for 5-MeO-DiPT because of the very similar structure and effects.
Chemistry[]
5-MeO-MiPT is in a class of compounds commonly known as tryptamines, and is the N-methyl-N-isopropyl homologue of the psychedelic, 5-MeO-DMT. The full name of the chemical is 5-methoxy-N-methyl-N-isopropyltryptamine.
5-MeO-MiPT causes the ehrlich reagent to turn purple then fade to faint blue. It causes the marquis reagent to go yellow through to black.[1]
Effects[]
This is an analogue of the more popular drug 5-MeO-DiPT (nicknamed "foxy methoxy") and has the nickname "moxy". Some users report the tactile effects of 5-MeO-DiPT without some of the unwanted side effects. At higher doses it becomes much more psychedelic sometimes being compared to 5-MeO-DMT. But at doses of 4-10 milligrams users find 5-MeO-MiPT to be a very euphoric and tactile chemical. Its energetic effects can be very strong at high doses, increasing normal heart rate considerably. Sounds can be amplified in perception to a point where synesthetic effects ("touching or/and tasting sounds") occur.
Pharmacodynamics[]
| Binding Sites | Binding Affinity Ki (μM)[2] |
|---|---|
| 5-HT1A | 0.058 |
| 5-HT2A | 0.163 |
| 5-HT2C | 1.3 |
| D1 | >25 |
| D2 | >25 |
| D3 | >25 |
| α1A | >12 |
| α2A | 5.3 |
| TAAR1 | >15 |
| H1 | 3.9 |
| SERT | 3.3 |
| DAT | >26 |
| NET | >22 |
Dosage[]
Please be aware that dosages with this compound seem to vary from individual to individual. Be careful, always start low. Based on many anecdotal reports,[3][4] dosages can be classified as followed:
| Smoked | Oral | |
|---|---|---|
| Threshold | 5 mg | 3 mg |
| Light | 5 - 10 mg | 3 - 7 mg |
| Common | 10 - 15 mg | 7 - 15 mg |
| Strong | 15 - 20 mg | 15 - 20 mg |
| Heavy | 20 mg + | 20 mg + |
Orally, 5-MeO-MiPT is active at 4-6 mg. The drug can also be smoked, but unlike most other tryptamines, this route requires a much higher dosage. 10–20 mg is usually smoked. It typically produces a very strong odor.
Some users report activity as low as 1 mg while others report no activity up to 20 mg, this compound seems to be highly sensitive to the individual and any potential researchers should keep this in mind. Titrating the dose would be especially important with this compound.
Some users report little to no visual activity until doses of 10 mg or higher are taken. This chemical proves very useful for opening up and expressing oneself much like MDMA (3,4-methylenedioxymethamphetamine) and may be a useful chemical in psychedelic therapy.
Pharmacology[]
The mechanism that produces the hallucinogenic and entheogenic effects of 5-MeO-MiPT is thought to result primarily from 5-HT2A receptor agonism, although additional mechanisms of action such as inhibition of MAO may be involved also.[5][6] While 5-MeO-MiPT binds most strongly to 5-HT1A receptors, it also shows fairly strong binding affinity to the SERT and NET, thereby acting as a moderately potent serotonin-norepinephrine reuptake inhibitor.[7] These mechanisms may help explain why there are many anecdotal reports of anti-depressant and anxiolytic effects from modest doses of this compound. For example, SNRIs such as venlafaxine are commonly prescribed to treat depression, and the 5-HT1A agonist buspirone is prescribed primarily for treatment of anxiety.
Reagent Results[]
Exposing compounds to the reagents gives a colour change which is indicative of the compound under test. The following test results are from protestkit.
| 5-MeO-MiPT | Marquis | Mecke | Mandelin | Liebermann | Ehrlich | Hofmann | Simon’s |
|---|---|---|---|---|---|---|---|
| Freebase | Orange to brown | Orange red | Deep greenish brown | Unknown | Purple | No reaction | No reaction |
| HCl | Orange to brown | Red to brown | Greenish brown | Brown | Violet to purple | Green | Unknown |
Dangers[]
The toxicity of 5-MeO-MiPT is not known, but as with all research chemicals, doses should be carefully weighed on an accurate milligram scale and users should take caution because overdoses are not listed. There are many reports of vasoconstriction with it as well. There is no known documentation of death attributed to the use of 5-MeO-MiPT alone.
Note - Some users report that they have a decrease of energy the next day after dosing. Please keep this in mind if you ever take this substance.
Legal status[]
Canada[]
5-MeO-MiPT is not scheduled in Canada.[citation needed]
China[]
As of October 2015 5-MeO-MiPT is a controlled substance in China.[8]
Luxembourg[]
In Luxembourg, 5-MeO-MiPT is not cited in the list of prohibited substances.[9] Therefore, it is still a legal substance.
United Kingdom[]
5-MeO-MiPT is a Class A drug in the United Kingdom as are most ethers of ring-hydroxy tryptamines.[citation needed]
United States[]
5-MeO-MiPT is unscheduled at the federal level in the United States,[10] but it could be considered an analog of 5-MeO-DiPT, in which case purchase, sale, or possession could be prosecuted under the Federal Analog Act.
Florida[]
"5-Methoxy-N-methyl-N-isopropyltryptamine" is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess in the state of Florida.[11]
See also[]
- MIPT
- 5-MeO-DMT
- 5-MeO-DiPT
- 5-MeO-MET
References[]
- ^ Spratley, Trinette (2004). "Analytical Profiles for Five "Designer" Tryptamines" (PDF). Microgram Journal. 3 (1–2): 55. Retrieved 2013-10-09.
- ^ Rickli A.; Moning O.D.; Hoener M.C.; Liechti M.E. (2016). "Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens" (PDF). European Neuropsychopharmacology. 26 (8): 1327–37. doi:10.1016/j.euroneuro.2016.05.001. PMID 27216487. S2CID 6685927.
- ^ "Erowid Online Books : "TIHKAL" - #40 5-MEO-MIPT". www.erowid.org. Retrieved 2021-06-01.
- ^ "5-MeO-MIPT (also 5-Methoxy-N,N-Methylisopropyltryptamine) : Erowid Exp: Main Index". www.erowid.org. Retrieved 2021-06-01.
- ^ Repke DB, Grotjahn DB, Shulgin AT (July 1985). "Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents". Journal of Medicinal Chemistry. 28 (7): 892–6. doi:10.1021/jm00145a007. PMID 4009612.
- ^ Nagai F, Nonaka R, Satoh Hisashi Kamimura K (March 2007). "The effects of non-medically used psychoactive drugs on monoamine neurotransmission in rat brain". European Journal of Pharmacology. 559 (2–3): 132–7. doi:10.1016/j.ejphar.2006.11.075. PMID 17223101.
- ^ Ray, T. S. (2010). "Psychedelics and the Human Receptorome". PLOS ONE. 5 (2): e9019. Bibcode:2010PLoSO...5.9019R. doi:10.1371/journal.pone.0009019. PMC 2814854. PMID 20126400.
- ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.
- ^ Loi du 19 février 1973 concernant la vente de substances médicamenteuses et la lutte contre la toxicomanie.
- ^ 21 CFR — SCHEDULES OF CONTROLLED SUBSTANCES §1308.11 Schedule I.
- ^ Florida Statutes - Chapter 893 - DRUG ABUSE PREVENTION AND CONTROL
External links[]
- Designer drugs
- Psychedelic tryptamines